ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 623,34
0,68%
Dow Jones
38 784,01
0,02%
DAX
18 122,48
0,27%
Brent Oil
84,47
0,68%
Bitcoin
65 187,57
-1,95%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Biohaven Ltd (BHVN)

  7. Biohaven Ltd (BHVN) Actualités

BHVN Biohaven Ltd

33,87
0,88 (2,67%)
Dernière mise à jour : 16:31:24
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Biohaven Ltd BHVN NYSE Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,88 2,67% 33,87 16:31:24
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
33,22 33,01 34,24 32,99
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
29/5/202413:30PRNUSBiohaven Showcases Broad Innovative Portfolio and Pipeline..
29/5/202413:15PRNUSBiohaven Doses First Patient with its Novel Trop-2 Directed..
17/5/202422:42EDGAR2Form 8-K - Current report
17/5/202422:41EDGAR2Form 424B7 - Prospectus [Rule 424(b)(7)]
09/5/202422:16EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/5/202422:14EDGAR2Form 8-K - Current report
09/5/202422:05PRNUSBiohaven Reports First Quarter 2024 Financial Results and..
22/4/202422:05PRNUSBiohaven Announces Closing of Public Offering and Full..
17/4/202422:05PRNUSBiohaven Announces Proposed Public Offering of Common Shares
13/4/202415:00PRNUSBiohaven Showcases Innovative Neuroscience Portfolio with 20..
29/2/202422:16EDGAR2Form 8-K - Current report
29/2/202422:05PRNUSBiohaven Reports Fourth Quarter and Full Year 2023 Financial..
08/1/202413:30EDGAR2Form 8-K - Current report
08/1/202413:30PRNUSBiohaven Highlights Progress Across Innovative Portfolio and..
02/1/202413:00PRNUSBiohaven to Present at the 42nd Annual J.P. Morgan..
01/12/202322:30PRNUSBiohaven Presents Expanded EEG and Safety Data for BHV-7000..
14/11/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202322:05PRNUSBiohaven Reports Third Quarter 2023 Financial Results and..
16/10/202313:00PRNUSBiohaven Presents Preclinical Data Demonstrating..
05/10/202322:05EDGAR2Form 8-K - Current report
05/10/202322:05PRNUSBiohaven Announces Closing of Public Offering and Full..
04/10/202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/10/202305:56PRNUSBiohaven Announces Pricing of $225 Million Public Offering..
03/10/202303:41EDGAR2Form 8-K - Current report
02/10/202323:09EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/10/202323:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/10/202322:36PRNUSBIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
02/10/202322:01EDGAR2Form S-3ASR - Automatic shelf registration statement of..
27/9/202312:58EDGAR2Form 8-K - Current report
14/9/202313:00PRNUSBiohaven Completes Enrollment in Pivotal Phase 3 Study of..
05/9/202313:00PRNUSBiohaven Announces Positive Data from its Exploratory..
31/7/202323:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/7/202322:29EDGAR2Form 8-K - Current report
31/7/202315:31PRNUSBiohaven's Taldefgrobep Alfa Receives EU Orphan Drug..
31/7/202312:59PRNUSBiohaven Reports Second Quarter 2023 Financial Results and..
28/7/202322:35EDGAR2Form 8-K - Current report
27/7/202314:42DJNBiohaven Told That FDA Won't Review NDA Application for..
27/7/202313:00PRNUSBiohaven Provides Preliminary EEG Data Update for Kv7..

Dernières Valeurs Consultées

NYSE
BHVN
Biohaven
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés